TacticScaleWhat Pacira Biosciences Does & How It Makes Money (PCRX)
Updated October 2026 · reflects Pacira Biosciences's latest reported financials
Specialty drugmaker focused on non-opioid pain management products. It earns revenue mainly by selling its injectable pain drugs and the iovera cryoanalgesia device to US hospitals, surgeons and other healthcare practitioners.
How Pacira Biosciences makes money
It earns revenue mainly by selling its injectable pain drugs and the iovera cryoanalgesia device to US hospitals, surgeons and other healthcare practitioners. It also has a development, commercialization and supply agreement with Aratana Therapeutics for NOCITA, a veterinary version of its liposomal bupivacaine.
What Pacira Biosciences does
Pacira BioSciences is a US specialty drug company built around non-opioid pain management. Its lead product, EXPAREL, is a liposomal form of the local anesthetic bupivacaine used to manage pain after surgery. ZILRETTA is an extended-release steroid injection for osteoarthritis knee pain, and the iovera system is a handheld device that uses targeted cold to block pain signals from peripheral nerves. All of these are sold to healthcare practitioners in the United States. The company is also moving into regenerative health with PCRX-201, a gene therapy vector platform designed to be given locally, with osteoarthritis as a potential target. Through an agreement with Aratana Therapeutics, it supplies a veterinary liposomal bupivacaine sold as NOCITA. Pacira was incorporated in 2006, changed its name from Pacira Pharmaceuticals in April 2019, and is headquartered in Brisbane, California.
Products & services
- EXPAREL (bupivacaine liposome injectable suspension)
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension)
- iovera system (cryoanalgesia device)
- PCRX-201 (gene therapy, in development)
- NOCITA (veterinary bupivacaine liposome, partnered with Aratana)
What is Pacira Biosciences worth?
On an owner-earnings DCF, Pacira Biosciences's most-likely value is about $75 versus a recent price near $36 (106% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$47) with a margin of safety — so the honest verdict here is “Deeply discounted.” Fair value earns its keep only at the extremes, not in the wide middle.
On the financials alone, $36 is below even the no-growth floor ($47); the market's discount — expectations and sentiment beyond the numbers — is pricing in ≈ -2.8%/yr. A bargain only if that pessimism is overdone.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
ANI Pharmaceuticals (ANIP) · KPC Pharmaceuticals,Inc (600422.SS) · Collegium Pharmaceutical (COLL) · BioMarin Pharmaceutical (BMRN) · Arcus Biosciences (RCUS)